Name: Ifosfamide
Brand: Selleck Chemicals
SKU: S1302
Rating: 5 (21 reviews)

Aller à

Contrôle Qualité (Quality Control)

Lot : Pureté : 99.96%

99.96

Cibles apparentées	HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase
Autre Alkylating Agent Inhibiteurs	Berberine (Umbellatine) MNNG (1-Methyl-3-nitro-1-nitrosoguanidine)

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)

Lignées cellulaires	Type d'essai	Description de l'activité	PMID
SJ-GBM2	qHTS assay	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Cliquez pour voir plus de données expérimentales sur la lignée cellulaire

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Poids moléculaire	261.09	Formule	C₇H₁₅Cl₂N₂O₂P	Stockage (À compter de la date de réception)	3 ans-20°Cpoudre
N° CAS	3778-73-2	Télécharger le SDF		Stockage des solutions mères	1 an-80°Cen solvant 1 mois-20°Cen solvant
Synonymes	NSC109724, Isophosphamide			Smiles	C1CN(P(=O)(OC1)NCCCl)CCCl

Solubilité (Solubility)

In vitro
Lot:

DMSO : 52 mg/mL (199.16 mM)
(Le DMSO contaminé par l'humidité peut réduire la solubilité. Utiliser du DMSO frais et anhydre.)

Water : 52 mg/mL

Ethanol : 52 mg/mL

Calculateur de molarité

Masse	Concentration	Volume	Poids moléculaire
=	×	×

Calculateur de dilution Calculateur de poids moléculaire

In vivo Lot:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validé par les laboratoires Selleck. Si vous avez besoin d'ajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	2.600mg/ml (9.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 52 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validé par les laboratoires Selleck. Si vous avez besoin d'ajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	0.260mg/ml (1.00mM)	Taking the 1 mL working solution as an example, add 50 μL of 5.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculateur de formulation in vivo (Solution claire)

Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)

Dosage : mg/kg Poids moyen des animaux : g Volume de dosage par animal :μL Nombre d'animaux :

Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Résultats du calcul :

Concentration de travail : mg/ml;

Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH₂O, mélanger et clarifier.

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.

Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.

Mécanisme d'action (Mechanism of Action)

In vitro	Ifosfamide (50 mM) increases CYP3A4, CYP2C8, and CYP2C9 protein levels in hepatocytes, which thereby enhances their own rates of 4-hydroxylation in the cultured hepatocytes. This compound only induces CYP3A4 in one human hepatocyte culture that contained the polymorphically expressed CYP3A5 in addition to the more widely expressed CYP3A4. It is a prodrug metabolised in the liver by cytochrome P450 mixed-function oxidase enzymes to isofosforamide mustard, the active alkylating compound. This drug has produced favourable response rates in small cell lung cancer, paediatric solid tumours, non-Hodgkin's and Hodgkin's lymphoma, and ovarian cancer. It is highly cytotoxic to MCF-7 cells following stable transfection of CYP2B1 but exhibits no toxicity to parental tumor cells or to a beta-galactosidase-expressing MCF-7 transfectant, this cytotoxicity could be appreciably blocked by the CYP2B1 inhibitor metyrapone. When combined with Zoledronic acid, it is more effective than each agent alone in preventing tumor recurrence, improving tissue repair, and increasing bone formation as revealed by the analysis of trabecular architecture.
In vivo	Ifosfamide (100 mg/kg, 200 mg/kg and 400 mg/kg) injected intraperitoneally induces a dose dependent increase in bladder wet weight and Evans blue extravasation in mice. This compound reveals extensive cystitis characterized by acute inflammation with vascular congestion, edema, hemorrhage and fibrin deposition, neutrophil cell infiltration and epithelial denudation in mice. It shows intense reactivity to inducible nitric oxide synthase in the cytoplasm as well as intense and diffuse necrosis on hematoxylin and eosin staining.
Références	[1] https://pubmed.ncbi.nlm.nih.gov/9157990/ [2] https://pubmed.ncbi.nlm.nih.gov/1720382/ [3] https://pubmed.ncbi.nlm.nih.gov/8640822/ [4] https://pubmed.ncbi.nlm.nih.gov/15894525/ [5] https://pubmed.ncbi.nlm.nih.gov/11956484/

Informations sur l'essai clinique (Clinical Trial Information)

(données du https://clinicaltrials.gov, mis à jour le 2026-08-03)

Numéro NCT	Recrutement	Conditions	Promoteur/Collaborateurs	Date de début	Phases
NCT06239272	RECRUITING	Adipocytic Neoplasm; Liposarcoma; Atypical Fibroxanthoma; Angiomatoid Fibrous Histiocytoma; Fibrosarcoma NOS; Myxofibrosarcoma; Angiosarcoma; Osteosarcoma, Extraskeletal; Dedifferentiated Liposarcoma; Myxoid Liposarcoma; Pleomorphic Liposarcoma; Myxoid Pleomorphic Liposarcoma; Low Grade Fibromyxoid Sarcoma; Sclerosing Epithelioid Fibrosarcoma; Malignant Tenosynovial Giant Cell Tumor of Soft Tissue; Epithelioid Hemangioendothelioma; Glomus Tumor; Inflammatory Leiomyosarcoma; Leiomyosarcoma; Ossifying Fibromyxoid Tumor, Malignant; Myoepithelioma; Synovial Sarcoma; Epithelioid Sarcoma; Perineurioma, Malignant; Clear Cell Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Granular Cell Tumor, Malignant; Melanotic Malignant Nerve Sheath Tumor; Malignant Peripheral Nerve Sheath Tumor; Perivascular Epithelioid Tumor, Malignant; Intimal Sarcoma; Myoepithelial Carcinoma; Undifferentiated Sarcoma; Pleomorphic Sarcoma, Undifferentiated; Round Cell Sarcoma, Undifferentiated; NTRK-Rearranged Spindle Cell Neoplasm; Phosphaturic Mesenchymal Tumor, Malignant; Round Cell Sarcoma; Well Differentiated Liposarcoma; Giant Cell Tumor of Soft Parts NOS; Low Grade Myofibroblastic Sarcoma; Dermatofibrosarcoma Protuberans, Fibrosarcomatous	St. Jude Children's Research Hospital	2024-03-27	PHASE1; PHASE2
NCT02106988	ACTIVE_NOT_RECRUITING	Lymphoma	M.D. Anderson Cancer Center	2015-01-16	PHASE2
NCT07724457	NOT_YET_RECRUITING	Recurrent Burkitt Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory Burkitt Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements	National Cancer Institute (NCI)	2026-10-30	PHASE2; PHASE3
NCT07321912	RECRUITING	Osteosarcoma; Ewing Sarcoma	Milton S. Hershey Medical Center	2026-06-05	PHASE2
NCT02375204	ACTIVE_NOT_RECRUITING	Germ Cell Tumor; Teratoma; Choriocarcinoma; Germinoma; Mixed Germ Cell Tumor; Yolk Sac Tumor; Childhood Teratoma; Malignant Germ Cell Neoplasm; Extragonadal Seminoma; Non-seminomatous Germ Cell Tumor; Seminoma	Alliance for Clinical Trials in Oncology	2015-08-06	PHASE3
NCT05991388	RECRUITING	B-cell Non Hodgkin Lymphoma	University of Birmingham	2024-05-02	PHASE2; PHASE3

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Ifosfamide Agent alkylant

Poids moléculaire: 261.09

Contrôle Qualité (Quality Control)

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Solubilité (Solubility)

Calculateur de molarité

Calculateur de formulation in vivo (Solution claire)

Mécanisme d'action (Mechanism of Action)

Informations sur l'essai clinique (Clinical Trial Information)

Ifosfamide Agent alkylant

Poids moléculaire: 261.09

Contrôle Qualité (Quality Control)

Culture cellulaire, traitement et concentration de travail (Cell Culture, Treatment & Working Concentration)

Informations chimiques, stockage et stabilité (Chemical Information, Storage & Stability)

Solubilité (Solubility)

Calculateur de molarité

Calculateur de formulation in vivo (Solution claire)

Mécanisme d'action (Mechanism of Action)

Informations sur l'essai clinique (Clinical Trial Information)

Culture cellulaire, traitement et concentration de travail
(Cell Culture, Treatment & Working Concentration)